©2024 Stanford Medicine
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Not Recruiting
Trial ID: NCT00215605
Purpose
The purpose of this study is to determine the best and safest dose of XL184 administered
orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated
in tumor formation, growth and migration. To determine the highest safe dose, subjects will
receive different amounts of the drug. The first group of subjects will receive the lowest
dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be
increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20
subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184
in this population.
Official Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies
Stanford Investigator(s)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Eligibility
Inclusion Criteria:
- Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is
metastatic or unresectable for which standard curative measures do not exist or are no
longer effective
- Eastern Cooperative Oncology Group (ECOG) performance status
- Life expectancy greater than 3 months
- Adequate organ and marrow function
- Written informed consent
- Use of acceptable methods of contraception during the course of the study and for 3
months after completion of study
- In the MTD expanded cohort: at least 20 subjects with metastatic and/or
advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical
resection with measurable disease as defined by RECIST
Exclusion Criteria:
- Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin
C within 6 weeks) before the first scheduled dose of XL184
- Administration of an investigational drug within 30 days of the first dose of XL184
- Subject has not recovered from adverse events due to investigational agents or other
medications administered more than 4 weeks before study enrollment
- Known brain metastases
- Uncontrolled intercurrent illness
- Pregnancy or breastfeeding
- Known HIV positive
- Known allergy or hypersensitivity to any of the components of the XL184 formulation
Intervention(s):
drug: XL184
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ruth Lira
6507231367